GnRH agonists and antagonists. Current clinical status

Summary Gonadotrophin-releasing hormone (GnRH) analogues offer a novel approach for the non-steroidal manipulation of the reproductive endocrine axis. GnRH agonists are now effectively employed in the management of precocious puberty, prostate and breast cancer, endometriosis, uterine leiomyoma, polycystic ovarian disease, and various other disorders. Unfortunately, contraceptive applications of GnRH agonists have been disappointing. The availability of slow release depot formulations of GnRH agonists, and the development of GnRH antagonists may further optimise and extend the clinical application of these compounds. Similar content being viewed by others References Akhtar FB, Marshall GR, Wickings EJ, Nieschlag E. Reversible induction of azoopsermia in Rhesus monkeys by constant infusion of a gonadotropin-releasing hormone agonist using osmotic minipumps. Journal of Clinical Endocrinology and Metabolism 56: 534–540, 1983 Allen JM, Kerle DJ, Ware H, Doble A, Williams G, et al. Combined treatment with ketoconazole and luteinizing hormone-releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. British Medical Journal 287: 1766–1767, 1983 Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. New England Journal of Medicine 311: 643–645, 1984 Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). Journal of Clinical Endocrinology and Metabolism 63: 854–859, 1986 Asch RH, Siler-Khodr TM, Smith CG, Schally AV. Luteolytic effect of D-Trp6-luteinizing hormone-releasing hormone in the Rhesus monkey (Macaca Mulatta). Journal of Clinical Endocrinology and Metabolism 52: 565–571, 1981 Bergquist C, Nillius SJ, Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception 19: 497–506, 1979a Bergquist C, Nillius SJ, Wide L. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent. Lancet 2: 215–217, 1979b Bergquist C, Nillius SJ, Wide L. Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotropin. Contraception 22: 341–347, 1980 Bergquist C, Nillius SJ, Wide L, Lindgren A. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonists treatment for contraception. Fertility and Sterility 36: 339–342, 1981 Bergquist C, Nillius SJ, Wide L. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women. Fertility and Sterility 38: 190–193, 1982 Bhasin S, Heber D, Steiner BS, Handelsman DJ, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen. Journal of Clinical Endocrinology and Metabolism 60: 998–1003, 1985 Bhasin S, Swerdloff RS. Mechanisms of gonadotropin-releasing hormone agonist action in the human male. Endocrine Reviews 7: 106–114, 1986 Blankenstein MA, Henkelman MS, Klijn JGM. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. European Journal of Cancer and Clinical Oncology 21: 1493–1499, 1985 Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, et al. Use of a potent long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocrine Reviews 7: 24–33, 1986 Borghi MR, Niesvisky R, Balmaceda JP, Coy DH, Schally AV, et al. Administration of luteinizing hormone-releasing hormone analogs delays ovulation without affecting the luteal function in Rhesus monkeys. Fertility and Sterility 40: 678–682, 1983 Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R. Sustained suppression of testosterone production by the luteinizing hormone-releasing hormone agonist buserelin in patients with advanced prostate carcinoma: a new therapeutic approach? Lancet 1: 1097–1099, 1982 Brauner B, Thibaud E, Bischof P, Sizonenko PC, Rappaport R. Long-term results of GnRH analogue (buserelin) treatment in girls with central precocious puberty. Acta Paediatrica Scandinavica 74: 945–949, 1985 Cann CE, Henzl M, Burry K, Andreko J, Hanson F, et al. Reversible bone loss is induced by GnRH agonists. Endocrinology 118 (Suppl.): 37, 1986 Casper RF, Sheehan KL, Yen SSC. Chorionic gonadotropin prevents LRF agonist induced luteolysis in the human. Contraception 21: 471–478, 1980 Casper RF, Yen SSC. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing hormone factor. Science 205: 408–410, 1979 Cetel NS, Rivier J, Vale W, Yen SSC. The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone. Journal of Clinical Endocrinology and Metabolism 57: 62–65, 1983 Chang RJ, Laufer LR, Meldrum DR, Defazio J, Lu JKH, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. Journal of Clinical Endocrinology and Metabolism 56: 897–903, 1983 Coddington CC, Collins RL, Shawker TH, Anderson R, Loriaux DL, et al. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertility and Sterility 45: 624–629, 1986 Comite F, Cutler GB, Rivier J, Vale W, Loriaux DL, et al. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. New England Journal of Medicine 305: 1546–1550, 1981 Comite F, Pescovitz OH, Rieth KG, Dwyer AJ, Hench K, et al. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty. Journal of Clinical Endocrinology and Metabolism 59: 888–892, 1984a Comite F, Shawker TH, Pescovitz OH, Loriaux DL, Cutler G. Cyclical ovarian function resistant to treatment with an analogue of luteinizing hormone-releasing hormone in McCune-Albright syndrome. New England Journal of Medicine 311: 1032–1036, 1984b Couzinet B, Le Strat N, Brailly S, Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 63: 1031–1035, 1986 Crowley Jr WF, Comite F, Vale W, Rivier J, Loriaux DL, et al. Therapeutic use of pituitary desensitization with a long-acting LH-RH agonist: a potential new treatment for idiopathic precocious puberty. Journal of Clinical Endocrinology and Metabolism 52: 370–372, 1981 Eidne KA, Flanagan CA, Harris NS, Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. Journal of Clinical Endocrinology and Metabolism 64: 425–432, 1987. Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, et al. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH. Journal of Clinical Endocrinology and Metabolism, in press, 1988. Filicori M, Hall DA, Loughlin JS, Rivier J, Vale W, et al. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by an LHRH analogue. American Journal of Obstetrics and Gynecology 147: 726–727, 1983 Fleming R, Adam AH, Barlow DH, Black WP, McNaughton MC, et al. A new systematic treatment for infertile women with abnormal hormone profiles. British Journal of Obstetrics and Gynaecology 89: 80–83, 1982 Fleming R, Haxton MJ, Hamilton MPR, McCune GS, Black WP, et al. Successful treatment of infertile women with oligomenorrhea using a combination of an LHRH agonist and exogenous gonadotrophins. British Journal of Obstetrics and Gynaecology 92: 369–373, 1985 Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, et al. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome. Journal of Clinical Endocrinology and Metabolism 59: 801–805, 1984 Fraser HM. GnRH and its analogues: current therapeutic applications and new prospects. Drugs 27: 187–193, 1934 Fraser HM, Sandow J. Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumped-tailed Macaque monkey. Journal of Clinical Endocrinology and Metabolism 60: 579–584, 1985 Garnick MB, Glode LM (for the Leuprolide Study Group). Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine 311: 1281–1286, 1984 Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1: 1132–1134, 1981 Gonzales-Barcena D, Rangel-Garcia NE, Perez-Sanchez PL, Gutierrez-Damperio C, Garcia-Carrasco F, et al. Response to D-Trp6-LH-RH in advanced adenocarcinoma of pancreas. Lancet 2: 154, 1986 Gotfredsen A, Nilas L, Juel Riis B, Thomsen K, Christiansen C. Bone changes occurring spontaneously and caused by oestrogen in early postmenopausal women: a local or generalised phenomenon? British Medical Journal 292: 1098–1100, 1986 Gudmundsson JA, Nillius SJ, Bergquist C. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH. Contraception 30: 107–114, 1984 Hague WM, Abdulwahid NA, Jacobs HS, Craft I. Use of LH-RH analogue to obtain reversible castration in a patient with benign metastasizing leiomyoma. British Journal of Obstetrics and Gynaecology 93: 455–460, 1986 Harris DA, Van Vliet G, Egli CA, Grumbach MM, Kaplan SL, et al. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. Journal of Clinical Endocrinology and Metabolism 61: 152–159, 1985 Healy DL, Fraser HM, Lawson SL. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. British Medical Journal 289: 1267–1268, 1984 Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM. Towards removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone (LHRH) agonist commencing in the luteal phase. Journal of Clinical Endocrinology and Metabolism 63: 619–625, 1986 Hook WA, Karten M, Siriganian RP. Histamine release by structural analogs of LHRH. Federation Proceedings 44: 1323, 1985 Huhtaniemi I, Nikula H, Rannikko S. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue. Journal of Clinical Endocrinology and Metabolism 61: 698–704, 1985 Johnson DH, Linde R, Hainsworth JD, Vale W, Rivier J, et al. Effect of a luteinizing hormone-releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma: preliminary observations. Blood 65: 832–836, 1985 Jones RC. The effect of a luteinizing hormone-releasing hormone (LHRH) agonist (WY-40,972), levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat. Acta Endocrinologica 106: 282–288, 1984 Kahan A, Delrieu F, Amor B, Chiche R, Sted A. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1: 971–972, 1984 Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design: structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Reviews 7: 44–66, 1986 Kauli R, Pertzelan A, Ben-Zeev Z, Prager Lewin R, Kaufman H, et al. Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate: further experience. Clinical Endocrinology 20: 377–387, 1984 Kerle D, Williams G, Ware H, Bloom SR. Failure of long term luteinizing hormone-releasing hormone treatment for prostatic cancer to suppress serum luteinizing hormone and testosterone. British Medical Journal 289: 468–469, 1984 Klijn JGM, De Jong FH. Treatment with a luteinizing hormone-release hormone analogue (buserelin) in pre-menopausal patients with metastatic breast cancer. Lancet 1: 1213–1216, 1982 Klijn JGM, De Jong FH, Lamberts SWJ, Blankenstein MA. LHRH-agonist treatment in clinical and experimental human breast cancer. Journal of Steroid Biochemistry 23: 867–873, 1985a Klijn JG, De Voogt HJ, Schroeder FH, De Jong FH. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet 2: 493, 1985b Koutsilieris M, Faure N, Tolis G, Laroche B, Roberts G, et al. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology 27: 221–228, 1986 Labrie F, Belanger A, Dupont A, Emond J, Lacoursiere Y, et al. Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet 2: 1090, 1984 Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry 23: 833–841, 1985 Labrie F, Dupont A, Belanger A, St Arnaud R, Giguere M, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews 7: 67–74, 1986 Laron Z, Kauli R, Ben Zeev A, Comaru Schally AM, Schally AV. D-Trp6 analogue of luteinizing hormone-releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet 2: 955–956, 1981 Laue L, Comite F, Hench K, Loriaux DL, Cutler Jr GB, et al. Precocious puberty associated with neurofibromatosis and optic gliomas: treatment with luteinizing hormone-releasing hormone analogue. American Journal of Diseases of Children 139: 1097–1100, 1985 Lemay A, Faure N, Labrie F. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-Ser[TBU]6, des-gly-NH2 10)-luteinizing hormone-releasing hormone ethylamide (buserelin) in normal women. Fertility and Sterility 37: 193–200, 1982a Lemay A, Faure N, Labrie F, Fazekas ATA. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge. Fertility and Sterility 39: 661–667, 1983 Lemay A, Labrie F, Belanger A, Raynaud JP. Luteolytic effect of intranasal administration of (D-Ser[TBU]6, des-gly-NH2 10)-luteinizing hormone-releasing hormone ethylamide in normal women. Fertility and Sterility 32: 646–651, 1979 Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertility and Sterility 41: 863–871, 1984 Lemay A, Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LHRH) agonist. Fertility and Sterility 38: 376–379, 1982b Lewis RW, Dowling KJ, Schally AV. D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons. Proceedings of the National Academy of Science of the USA 82: 2975–2979, 1985 Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. New England Journal of Medicine 305: 663–667, 1981 Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas ATA. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study. American Journal of Obstetrics and Gynecology 152: 1034–1038, 1985 Maheux R, Lemay A, Merat P. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyoma. Fertility and Sterility 47: 229–233, 1987 Mais V, Kazer RR, Cetel NS, Rivier J, Vale W, et al. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. Journal of Clinical Endocrinology and Metabolism 62: 1250–1255, 1986 Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocrine Reviews 7: 89–94, 1986 Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, et al. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone: effects on somatic growth and skeletal maturation. New England Journal of Medicine 309: 1286–1290, 1983 Meldrum DR, Chang RJ, Lu J, Vale W, Rivier J, et al. “Medical oophorectomy” using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. Journal of Clinical Endocrinology and Metabolism 54: 1081–1083, 1982 Meldrum DR, Pardridge WM, Karow WG, Rivier J, Vale W, et al. Hormonal effects of danazol and medical oophorectomy in endometriosis. Obstetrics and Gynecology 62: 480–485, 1983 Meldrum DR, Tsao Z, Monroe SE, Braunstein GD, Lu JKH, et al. Stimulation of LH with reduced bioactivity following GnRH agonist administration in women. Journal of Clinical Endocrinology and Metabolism 58: 755–760, 1984 Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233, 1985 Mongioi A, Maugeri G, Macchi N, Calogero A, Vicari E, et al. Effect on gonadotropin-releasing hormone analogue (GnRH-A) administration on serum gonadotropin and steroid levels in patients with polycystic ovarian disease. Acta Endocrinologica 111: 228–234, 1986 Monroe SE, Henzl MR, Martin MC, Schriock E, Lewis V, et al. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle. Fertility and Sterility 43: 361–368, 1985 Muse KN, Cetel NS, Futterman LA, Yen SSC. The premenstrual syndrome: effects of “medical ovariectomy”. New England Journal of Medicine 311: 1345–1349, 1984 Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, et al. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. Journal of Steroid Biochemistry 20: 129–135, 1984 Nillius SJ, Bergquist C, Wide L. Inhibition of ovulation in women by chronic treatment with a stimulatory LHRH analogue: a new approach to birth control? Contraception 17: 537–545, 1978 Parmar H, Phillips RH, Lightman SL, Edwards L. Early tumor exacerbation in patients treated with long acting analogues of gonadotropin releasing hormone. British Medical Journal 291: 1645, 1985 Pavlou SN, Debold CR, Island DP, Wakefield G, Rivier J, et al. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men. Journal of Clinical Endocrinology and Metabolism 63: 303–308, 1986a Pavlou SN, Interlandi JW, Wakefield G, Rivier J, Vale W, et al. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. Journal of Andrology 7: 228–233, 1986b Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism 58: 857–861, 1984 Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone-releasing hormone analogue therapy. Journal of Pediatrics 108: 47–54, 1986 Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet 2: 1284–1286, 1984 Pring DW, Maresh M, Fraser AC. Luteinizing hormone-releasing hormone agonist in women with endometriosis. British Medical Journal 287: 1718–1719, 1983 Rabin D, Evans RM, Alexander AN, Doelle GC, Rivier J, et al. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone. Journal of Andrology 5: 176–180, 1984 Redding TW, Schally AV, Tice TR, Meyers WE. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of (D-Trp6) luteinizing hormone-releasing hormone from injectable microcapsules. Proceedings of the National Academy of Science of the USA 226: 5845–5848, 1984 Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. Journal of Clinical Endocrinology and Metabolism 57: 571–579, 1983 Santen RJ, Demers LM, Max DT, Smith J, Stein BS, et al. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. Journal of Clinical Endocrinology and Metabolism 58: 397–400, 1984 Schmidt F, Sundaram K, Thau RB, Bardin CW. [Ac-D-NAL(2)1, 4FD-Phe2,D-Trp3, D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 29: 283–289, 1984 Schmidt-Gollwitzer M, Hardt M, Schmidt-Gollwitzer K, Von Derohe M, Nevinny-Stickel J. Influence of the LHRH analogue buserelin on cyclic ovarian function and on endometrium: a new approach to fertility control? Contraception 23: 187–195, 1981 Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertility and Sterility 44: 583–588, 1985 Schurmeyer TH, Knuth UA, Freischem CW, Sandow J, Akhtar FB, et al. Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. Journal of Clinical Endocrinology and Metabolism 59: 19–24, 1984 Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, et al. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology 26: 117–124, 1985 Shaw RW, Fraser HM. Use of superactive luteinizing hormone-releasing hormone (LHRH) agonist in the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology 91: 913–916, 1984 Shaw RW, Fraser HM, Boyle H. Intranasal treatment with luteinizing hormone-releasing hormone agonist in women with endometriosis. British Medical Journal 287: 1667–1669, 1983 Sheehan KL, Casper RF, Yen SSC. Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibility. Fertility and Sterility 37: 209–212, 1982a Sheehan KL, Casper RF, Yen SSC. Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor; a model for fertility control. Science 215: 170–172, 1982b Skarin G, Nillius SJ, Wide L. Early follicular phase luteinizing hormone-releasing hormone agonist administration: effect on follicular maturation and corpus luteum function in women. Contraception 25: 31–39, 1982a Skarin G, Nillius SJ, Wide L. Failure to induce early abortion by huge doses of a superactive LRH agonist in women. Contraception 26: 457–464, 1982b Smith Jr JA, Glode LM, Wettlaufer JN, Stein BS, Glass AG, et al. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 25: 106–114, 1985 Stanhope R, Adams J, Brook CGD. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin). Clinical Endocrinology 22: 795–806, 1985 Stein BS, Smith Jr JA. DES lead-in to use of luteinizing hormone-releasing hormone analogs in treatment of metastatic carcinoma of prostate. Urology 25: 350–353, 1985 Steingold KA, Judd HL, Nieberg RK, Lu JK, Chang RJ. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. American Journal of Obstetrics and Gynecology 154: 1241–1248, 1986 Styne DM, Harris DA, Egli CA, Conte FA, Kaplan SL, et al. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. Journal of Clinical Endocrinology and Metabolism 61: 142–157, 1985 Sundaram K, Connell KG, Wayne Bardin C, Somojlik E, Schally AV. Inhibition of pituitary-testicular function with (D-Trp6) luteinizing hormone-releasing hormone in Rhesus monkeys. Endocrinology 110: 1308–1314, 1982 Tolis G, Ackman D, Stellos A, Metha A, Labrie F, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with GnRH agonists. Proceedings of the National Academy of Science of the USA 79: 1658–1662, 1982 Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, et al. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemotherapy and Pharmacology 15: 171–173, 1985a Waxman J, Man A, Hendry WF, Whitfield HN, Besser GM, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. British Medical Journal 291: 1387–1388, 1985b Werlin LB, Hodgen GD. Gonadotropin-releasing hormone agonist suppresses ovulation, menses and endometriosis in monkeys: an individualized, intermittent regimen. Journal of Clinical Endocrinology and Metabolism 56: 844–848, 1983 Wierman ME, Beardsworth DE, Crawford JD, Crigler Jr JF, Mansfield MJ, et al. Adrenarche and skeletal maturation during luteinizing hormone-releasing hormone analogue suppression of gonadarche. Journal of Clinical Investigation 77: 121–126, 1986 Wierman ME, Beardsworth DE, Mansfield MJ, Badger TM, Crawford JD, et al. Puberty without gonadotropins: a unique mechanism of sexual development. New England Journal of Medicine 312: 65–72, 1985 Wilks JW. Inhibition of folliculogenesis in the monkey following early follicular phase administration of an LRH agonist. Acta Endocrinologica 106: 538–543, 1984 Author information Authors and Affiliations Rights and permissions About this article Cite this article Filicori, M., Flamigni, C. GnRH Agonists and Antagonists. Drugs 35, 63–82 (1988). https://doi.org/10.2165/00003495-198835010-00004 Published: Issue date: DOI: https://doi.org/10.2165/00003495-198835010-00004